What can we expect from long-acting formulations for schizophrenia?

Affiliations

¹ Division of Translational Neuroscience, Department of Psychiatry, University of Pennsylvania, Translational Research Laboratories, Philadelphia, PA 19104, USA. siegels@mail.med.upenn.edu

Comment

Steven J Siegel. Curr Psychiatry Rep. 2011 Aug.

. 2011 Aug;13(4):243-4.

doi: 10.1007/s11920-011-0206-2.

¹ Division of Translational Neuroscience, Department of Psychiatry, University of Pennsylvania, Translational Research Laboratories, Philadelphia, PA 19104, USA. siegels@mail.med.upenn.edu

No abstract available

Comment on

Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials.
Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Leucht C, et al. Schizophr Res. 2011 Apr;127(1-3):83-92. doi: 10.1016/j.schres.2010.11.020. Epub 2011 Jan 22. Schizophr Res. 2011. PMID: 21257294
Long-acting risperidone and oral antipsychotics in unstable schizophrenia.
Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Thwin SS, Vertrees JE, Liang MH; CSP555 Research Group. Rosenheck RA, et al. N Engl J Med. 2011 Mar 3;364(9):842-51. doi: 10.1056/NEJMoa1005987. N Engl J Med. 2011. PMID: 21366475 Clinical Trial.